Dr. Alan Tan
Claim this profileRush University Medical Center
Studies Kidney Cancer
Studies Renal Cell Carcinoma
15 reported clinical trials
26 drugs studied
Area of expertise
1Kidney Cancer
Stage IV
TFEb positive
TFE3 positive
2Renal Cell Carcinoma
Stage IV
TFEb positive
TFE3 positive
Affiliated Hospitals
Clinical Trials Alan Tan is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
More about Alan Tan
Clinical Trial Related5 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Alan Tan has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Avelumab
- Cabozantinib
- Axitinib
Breakdown of trials Alan Tan has run
Kidney Cancer
Renal Cell Carcinoma
Bladder Cancer
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alan Tan specialize in?
Alan Tan focuses on Kidney Cancer and Renal Cell Carcinoma. In particular, much of their work with Kidney Cancer has involved Stage IV patients, or patients who are TFEb positive.
Is Alan Tan currently recruiting for clinical trials?
Yes, Alan Tan is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Alan Tan has studied deeply?
Yes, Alan Tan has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Alan Tan?
Apply for one of the trials that Alan Tan is conducting.
What is the office address of Alan Tan?
The office of Alan Tan is located at: Rush University Medical Center, Chicago, Illinois 60612 United States. This is the address for their practice at the Rush University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.